Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity tropomyosin-related kinase receptor (TrkB) present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB (cAMP response element-binding protein) has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at (i) neurotrophic protein regulation in the central and peripheral nervous systems, and (ii) diminishment of the production of reactive oxygen species (ROS) and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines.

Institut Galien Paris Sud CNRS UMR 8612 University of Paris Sud Université Paris Saclay LabEx LERMIT Châtenay Malabry cedex France

Institute of Physics ELI Beamlines Academy of Sciences of the Czech Republic Prague Czech Republic

Zobrazit více v PubMed

Angelov B, Angelova A, Drechsler M, Garamus VM, Mutafchieva R, Lesieur S. Identification of large channels in cationic PEGylated cubosome nanoparticles by synchrotron radiation SAXS and Cryo-TEM imaging. Soft Matter. 2015;11:3686–3692. PubMed

Angelov B, Angelova A, Filippov SK, Drechsler M, Štěpánek P, Lesieur S. Multicompartment lipid cubic nanoparticles with high protein upload: Millisecond dynamics of formation. ACS Nano. 2014;8:5216–5226. PubMed

Angelov B, Garamus VM, Drechsler M, Angelova A. Structural analysis of nanoparticulate carriers for encapsulation of macromolecular drugs. J Mol Liq. 2017;235:83–89.

Angelova A, Angelov B, Drechsler M, Lesieur S. Neurotrophin delivery using nanotechnology. Drug Discovery Today. 2013;18:1263–1271. PubMed

Angelova A, Angelov B, Mutafchieva R, Lesieur S. Biocompatible mesoporous and soft nanoarchitectures. J Inorg Organomet Polym. 2015;25:214–232.

Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4:299–309. PubMed

Cheng A, Wan R, Yang JL, Kamimura N, Son TG, Ouyang X, Luo Y, Okun E, Mattson MP. Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. Nat Commun. 2012;3:1250. PubMed PMC

Geisler JG, Marosi K, Halpern J, Mattson MP. DNP, mitochondrial uncoupling, and neuroprotection: A little dab’ll do ya. Alzheimers Dement. 2017;13:582–591. PubMed PMC

Géral C, Angelova A, Lesieur S. From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF) Pharmaceutics. 2013;5:127–167. PubMed PMC

Guerzoni LPB, Nicolas V, Angelova A. In vitro modulation of TrkB receptor signaling upon sequential delivery of curcumin-DHA loaded carriers towards promoting neuronal survival. Pharm Res. 2017;34:492–505. PubMed

Ingallina C, Rinaldi F, Bogni A, Ponti J, Passeri D, Reggente M, Rossi M, Kinsner-Ovaskainen A, Mehn D, Rossi F, Botta B, Carafa M, Marianecci C. Niosomal approach to brain delivery: Development, characterization and in vitro toxicological studies. Int J Pharm. 2016;511:969–982. PubMed

Liu Y, An S, Li J, Kuang Y, He X, Guo Y, Ma H, Zhang Y, Ji B, Jiang C. Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice. Biomaterials. 2016;80:33–45. PubMed

Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013;14:401–416. PubMed

Markham A, Cameron I, Franklin P, Spedding M. BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur J Neurosci. 2004;20:1189–1196. PubMed

Re F, Gregori Ma, Masserini M. Nanotechnology for neurodegenerative disorders. Nanomedicine. 2012;8:S51–58. PubMed

Su B, Ji YS, Sun XL, Liu XH, Chen ZY. Brain-derived neurotrophic factor (BDNF)-induced mitochondrial motility arrest and presynaptic docking contribute to BDNF-enhanced synaptic transmission. J Biol Chem. 2014;289:1213–1226. PubMed PMC

Todorova V, Blokland A. Mitochondria and synaptic plasticity in the mature and aging nervous system. Curr Pharmacol. 2017;15:166–173. PubMed PMC

Viral M, Mira H. Regulation of neurogenesis by neurotrophins during adulthood: Expected and unexpected roles. Front Neurosci. 2016;10:26. PubMed PMC

Zhang G, Bowling H, Hom N, Kirshenbaum K, Klann E, Chao MV, Neubert TA. In-depth quantitative proteomic analysis of de novo protein synthesis induced by brain-derived neurotrophic factor. J Proteome Res. 2014;13:5707–5714. PubMed PMC

Sustained CREB phosphorylation by lipid-peptide liquid crystalline nanoassemblies

Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery

Plasmalogen-Based Liquid Crystalline Multiphase Structures Involving Docosapentaenoyl Derivatives Inspired by Biological Cubic Membranes

Cubic Liquid Crystalline Nanostructures Involving Catalase and Curcumin: BioSAXS Study and Catalase Peroxidatic Function after Cubosomal Nanoparticle Treatment of Differentiated SH-SY5Y Cells

Liquid Crystalline Nanostructures as PEGylated Reservoirs of Omega-3 Polyunsaturated Fatty Acids: Structural Insights toward Delivery Formulations against Neurodegenerative Disorders